{"groups":[{"description":"Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.","id":"FG000","title":"Arm A (CPX-351)"},{"description":"Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.","id":"FG001","title":"Arm B (7+3)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"153"},{"groupId":"FG001","numSubjects":"156"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"10"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"131"},{"groupId":"FG001","numSubjects":"146"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}